Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with

Malvaceae cancer chemopreventive herbal nutraceutical pharmacodynamic pharmacokinetic tiliroside

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 15 07 2024
accepted: 04 10 2024
medline: 31 10 2024
pubmed: 31 10 2024
entrez: 31 10 2024
Statut: epublish

Résumé

Cancer is the second most widespread cause of mortality following cardiovascular disorders, and it imposes a heavy global burden. Nowadays, herbal nutraceutical products with a plethora of bioactive metabolites represent a foundation stone for the development of promising chemopreventive and anticancer agents. Certain members of the family Malvaceae have traditionally been employed to relieve tumors. The literature concerning the chemopreventive and anticancer effects of the plant species along with the isolated cytotoxic phytometabolites was reviewed. Based on the findings, comprehensive computational modelling studies were performed to explore the pharmacokinetic and pharmacodynamic profiles of the reported cytotoxic metabolites to present basis for future plant-based anticancer drug discovery. All the available information about the anticancer research in family Malvaceae and its cytotoxic phytometabolites were retrieved from official sources. Extensive search was carried out using the keywords Malvaceae, cancer, cytotoxicity, mechanism and signalling pathway. Pharmacokinetic study was performed on the cytotoxic metabolites using SWISS ADME model. Acute oral toxicity expressed as median lethal dose (LD One hundred forty-five articles were eligible in the study. Several tested compounds showed safe pharmacokinetic properties. Also, the molecular docking study showed that the bioactive metabolites possessed agreeable binding affinities to EGFR kinase enzyme. Tiliroside (25), boehmenan (30), boehmenan H (31), and isoquercetin (22) elicited the highest binding affinity toward the enzyme with a score of -10.4, -10.4, -10.2 and -10.1 Kcal/mol compared to the reference drug erlotinib having a binding score equal to -9 Kcal/mol. Additionally, compounds 25 and 31 elicited binding free energies equal to -42.17 and -42.68 Kcal/mol, respectively, comparable to erlotinib. Overall, the current study presents helpful insights into the pharmacokinetic and pharmacodynamic properties of the reported cytotoxic metabolites belonging to family Malvaceae members. The molecular docking and dynamic simulations results intensify the roles of secondary metabolites from medicinal plants in fighting cancer.

Identifiants

pubmed: 39478959
doi: 10.3389/fphar.2024.1465055
pii: 1465055
pmc: PMC11521888
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1465055

Informations de copyright

Copyright © 2024 Sameh, Elissawy, Al-Sayed, Labib, Chang, Yu, Chang, Yang and Singab.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Salma Sameh (S)

Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.

Ahmed M Elissawy (AM)

Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
Center of Drug Discovery Research and Development, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.

Eman Al-Sayed (E)

Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.

Rola M Labib (RM)

Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.

Hsueh-Wei Chang (HW)

Department of Biomedical Science and Environmental Biology, and PhD Program in Life Sciences, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan.

Szu-Yin Yu (SY)

School of Pharmacy and Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.

Fang-Rong Chang (FR)

School of Pharmacy and Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.

Shyh-Chyun Yang (SC)

School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

Abdel Nasser B Singab (ANB)

Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
Center of Drug Discovery Research and Development, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.

Classifications MeSH